Jagsonpal Pharmaceuticals Reports Q2FY27 Results and Inorganic Expansion
Jagsonpal Pharmaceuticals Ltd · Press Release · 29 Oct 2026, 12:11 am
Jagsonpal Pharmaceuticals Reports Q2FY27 Results and Inorganic Expansion Jagsonpal Pharmaceuticals reported consolidated revenue growth of 29% YoY to ₹964 Mn in Q2FY27, while standalone revenue grew 9.3% YoY to ₹814 Mn with an EBITDA margin of 22.7% (₹185 Mn) and PAT of ₹126 Mn. In H1FY27, standalone revenue rose 9.0% YoY to ₹1,636 Mn and PAT rose 10.3% YoY to ₹258 Mn. Growth was aided by consolidating Aequitas Healthcare (acquired for ₹208 Mn cash) and completing the Group Pharma Wellness acquisition on 1st Oct'26, supporting the target to reach ₹5,000 Mn annual revenue by 2028.
Original exchange filing (PDF)
More announcements from Jagsonpal Pharmaceuticals Ltd
- Earning call transcript for Jagsonpal Pharmaceuticals Limited Q2 FY 27 Earning Conference Call on October 29, 2026 at 2:00 P.M · 03 Nov 2026
- Audio Recording of Jagsonpal Pharmaceuticals Limited Q2 FY27 Earnings Conference call on October 29, 2026 at 02:00 P.M. · 29 Oct 2026
- Press Release for Unaudited Financial Results for the quarter September 30, 2026 · 29 Oct 2026
- Unaudited Financial Results (Standalone & Consolidated for the quarter and half year ended September 30, 2026. · 28 Oct 2026
- Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 28 Oct 2026
- Outcome of Board Meeting held on October 28, 2026 along with Unaudited Financial Results(Standalone & Consolidated) for the quarter and half year ended September 30, 2026 · 28 Oct 2026
- JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 28 Oct 2026
- Intimation of Analysts/Investors Conference Call · 29 Oct 2026
